Healthy
Conditions
Brief summary
The purpose of this study is to assess safety, tolerability of LCB01-0371 after fasting/non-fasting food taken in healthy male subjects.
Detailed description
A Randomized, Open-label, Single dose, Crossover, Phase Ⅰ Trial to evaluate the effect of food on the pharmacokinetics of LCB01-0371 in healthy male subjects.
Interventions
DRUGLCB01-0371 Tablet 800 mg(R)
Reference: taken drug before meal
DRUGLCB01-0371 Tablet 800 mg(T)
Test: taken drug after meal
Sponsors
LigaChem Biosciences, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
20 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy male between 20 and 40 years of age at the time of screening with body mass index (BMI) between 19 kg/m2 and 28 kg/m2 at the time of screening 2. Appropriated for a medical examination by interview,Vital sign,physical examination, local laboratory test result and 12-lead ECG 3. Capable of performing follow up visit, blood sampling 4. Agree to continue to use a medically reliable dual contraception and not to donate sperm in this protocol for the duration of the study and for 28 days after last dose of investigational product 5. Capable of giving written informed consent, willing to participate in this clinical trial, and willing to comply with all study requirements
Exclusion criteria
1. History of clinically significant disease such as digestive system, respiratory, musculoskeletal, cardiovascular, endocrine, neuropsychiatry, hematology, cardiovascular system 2. History of gastrointestinal problem (e.g. Crohn's disease, gastro-intestinal ulcer) within 180 days possibly affecting absorption of clinical trial drugs, or history of surgery (except simple appendectomy and herniotomy) 3. History of hypersensitivity reaction or history of clinically significant hypersensitivity reaction to LCB01-0371 or same class of the study drugs (linezolid) or other drugs including aspirin and antibiotics(except non active allergic rhinitis) 4. History of drug abuse or positive result at urine drug screening test at screening visit 5. Intake drug which expected to chronic influence of drug absorption or elimination within 30 days prior to screening visit 6. Other: Patients considered unable perform for the study by the investigator concerning
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Adverse events | From date of randomization until follow up after 7 days from last hospital discharge |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacokinetics: AUClast(Area under the plasma concentration) | 0(predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 24hours |
| Pharmacokinetics: Cmax(Peak plasma concentration) | 0(predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 24hours |
Countries
South Korea
Outcome results
None listed